Transitional Cell Carcinoma — Trials

Transitional Cell Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

734 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 253
Recruiting: 125
Ph III recruiting: 17
Growth YoY: +47.5%
Industry share: 31%
Top sponsor: National Cancer Institute (NCI)
Termination share: 44%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (119)

clinicaltrialsPublishedShowing 51–53 of 53 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT01353222	DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma	terminated	Phase 2	142	DendreonINDUSTRY	1	May 25, 2017	clinicaltrials
NCT02479178	A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck(iNSITE2)	terminated	Phase 2	73	BIND TherapeuticsINDUSTRY	2	Apr 14, 2016	clinicaltrials